Table 4:

Clinical trials underway to treat SARS-CoV-2 infection (source: clinicaltrials.org and Clinical Trials Arena)

Drugs	Target/mechanism
Remdesivir	Inhibits viral RNA synthesis
Danoprevir + Ritonavir	Protease inhibitor, Antiretroviral
Lopinavir + Ritonavir	Protease inhibitor
Hydroxychloroquine	Inhibits lysosomal activity (Discontinued)
Telmisartan	Angiotensin receptor blocker
Rintatolimod	Recombinant Interferon Alfa-2B
Meplazumab	Mab against CD147 membrane glycoprotein
Favipiravir	RNA dependent RNA polymerase
Galidesivir	Inhibits viral RNA synthesis
Nitazoxanide	Interfere with pyruvate:ferredoxin oxidoreductase
ACE inhibitors/ARB	Angiotensin-converting enzyme inhibitor, Angiotensin receptor blockers
Convalescent serum	Virus-neutralizing antibodies
Monoclonal antibodies to SARS-CoV-2	Virus-neutralizing antibodies
Baricitinib	Janus Kinase inhibitor
Mesenchymal stem cells	Cell therapy
Famotidine	H2 blocker
Interferon β−1b	Antiviral immune response
Peginterferon lambda alfa-1a	Antiviral immune response
SARS-CoV-2-specific T-cells	Cytotoxic T-cells
NT-17	Recombinant IL-17
Isotretinoin	Papain-like protease inhibitor
MK-4482	Antiviral
TXA127	Angiotensin 1–7
Clevudine	Pyrimidine analogue for HBV treatment
Opaganib	Sphingosine kinase-2 inhibitor